Quest Spring 2013 : Page 3

coding region of a gene located on the long arm of chromosome 17. In the families examined, all 18 men with prostate cancer from these families carried the mutation. Within the carrier families, the mutation was more common in men with prostate cancer than those without prostate cancer. Most important for continuing study, the “C” allele -higher risk of PCa SNPs clinical characteristics of the prostate cancer in those families included Almost all features of high-risk common disease. SNPs have This particular mutation, HOXB13, “T” allele – lower risk of PCa only 2 may confer aggressiveness. alleles: While this finding could be a basis for early-targeted screening of men at A,T,G,or C risk for prostate cancer and possibly aggressive prostate cancer, it also 3 Regions of 8q24 Associated with shows how complicated genetic Prostate Cancer Susceptibility research is. SNPs The frequency of HOXB13 mutations was highest in families REGION 2 rs16901979 (A) from Nordic countries and not found in African, Ashkenazi breast REGION 3 rs6983267 (G) colon POU5F1P1 Jewish or other descents. rs4008482 rs13254738 rs6985361 Robin Leikin, PhD, the Scientific Program Director for the Robert H. Lurie Comprehensive Cancer Center and Phillip Cooper, Research Assistant for Dr. Catalona, getting ready to submit the SPORE grant (see page 1 article). 128.14-128.28 Broad11934905 128.47-128.54 REGION 1 REGION 4 128.54-128.62 rs1447295 (A) rs10090154 rs17837688 rs4242382 rs7000448 Direction Clearly, we have a long way to go in finding genetic biomarkers that can distinguish between aggressive and non-aggressive prostate cancer. Under my clinical direction and the basic science direction of John Witte, PhD, we are developing a new study to: 1) Find ways to identify men with aggressive prostate cancer who are enrolled in active surveillance programs, 2) Find novel biomarkers that indicate aggressive prostate cancer, 3) Discover cell signaling pathways that would result in potential therapeutic targets, and 4) Examine aggressive disease in men of different ethnic backgrounds. MYC Amundadottir et al. (2006) Nat Genetics 38: 652 Freedman et al. (2006) PNAS 103: 14068 Gudmundsson et al. (2007) Nat Genetics 39: 631 Haiman et al. (2007) Nat Genetics 39: 658 Yeager et al. (2007) Nat Genetics 39: 645 Robbins et al (2007) Genome Res 17:1717 Salinas et al (2008) CEBP 17:1203 Ch 8 128.0-129.0 Mb Dear Readers, New Agent For Detecting Location of Recurring Prostate Cancer A T he FDA approved the production and use of Choline C 11 injections to help detect recurrent prostate cancer . This PET imaging agent is especially useful when PSA levels are increasing after earlier treatment for prostate cancer but conventional imaging tests don’t show signs of cancer. The Choline C 11 injection is administered intravenously to produce an image that helps to locate specific body sites for follow-up tissue sampling and testing in men with recurrent prostate cancer. It does not replace tissue sampling and testing but assists in identifying areas for sampling when PSA increases indicate a recurrence but other results have not shown cancer. The Mayo Clinic is the first FDA-approved facility to produce Choline C 11 injection. Choline C 11 injection must be produced in a specialized facility and administered to patients shortly after its production. In studies submitted to the FDA, at least half of the patients who had cancers detected on PET scans with Choline C 11 also had recurrent prostate cancer confirmed by tissue sampling of the same area. False positives were also reported in 15 to 47 percent of patients, underscoring the need to confirm results with tissue samples. Identifying the location of recurrent prostate cancer is important for further treatment decisions. fter 13 years with the Urological Research Foundation, this issue is my last as Editor of Q UEST . I greatly respect the diligence and hard work Dr. Catalona, his research collaborators, and the URF have undertaken and the progress they have accomplished. And I am proud that I have had a part in sharing and explaining the important work they are doing in the field of prostate cancer. Also, I want to express my admiration and gratitude to the courageous men who have shared their stories, and to the thousands of readers who have followed this important subject with us throughout these past many years. As I take on new projects in new arenas, I will be an avid Q UEST reader who looks forward to more reports on Dr. Catalona's successes and continued progress in the treatment and cure of prostate cancer. Cecilia Lacks, PhD Editor of Q UEST 3 Q UEST Spring 2013

New Agent For Detecting Location Of Recurring Prostate Cancer

The FDA approved the production and use of Choline C 11 injections to help detect recurrent prostate cancer. This PET imaging agent is especially useful when PSA levels are increasing after earlier treatment for prostate cancer but conventional imaging tests don’t show signs of cancer. The Choline C 11 injection is administered intravenously to produce an image that helps to locate specific body sites for follow-up tissue sampling and testing in men with recurrent prostate cancer. It does not replace tissue sampling and testing but assists in identifying areas for sampling when PSA increases indicate a recurrence but other results have not shown cancer. The Mayo Clinic is the first FDA-approved facility to produce Choline C 11 injection. Choline C 11 injection must be produced in a specialized facility and administered to patients shortly after its production. In studies submitted to the FDA, at least half of the patients who had cancers detected on PET scans with Choline C 11 also had recurrent prostate cancer confirmed by tissue sampling of the same area. False positives were also reported in 15 to 47 percent of patients, underscoring the need to confirm results with tissue samples. Identifying the location of recurrent prostate cancer is important for further treatment decisions.

Dear Readers

After 13 years with the Urological Research Foundation, this issue is my last as Editor of QUEST. I greatly respect the diligence and hard work Dr. Catalona, his research collaborators, and the URF have undertaken and the progress they have accomplished. And I am proud that I have had a part in sharing and explaining the important work they are doing in the field of prostate cancer. Also, I want to express my admiration and gratitude to the courageous men who have shared their stories, and to the thousands of readers who have followed this important subject with us throughout these past many years. As I take on new projects in new arenas, I will be an avidQUEST reader who looks forward to more reports on Dr. Catalona's successes and continued progress in the treatment and cure of prostate cancer. Cecilia Lacks, PhD Editor of QUEST

Previous Page Next Page

Publication List